CytomX Therapeutics (NASDAQ:CTMX) Issues Earnings Results

CytomX Therapeutics (NASDAQ:CTMX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.14) by $0.04, FiscalAI reports. CytomX Therapeutics had a negative return on equity of 54.37% and a negative net margin of 166.40%.The company had revenue of $10.26 million for the quarter, compared to the consensus estimate of $4.68 million.

Here are the key takeaways from CytomX Therapeutics’ conference call:

• Varseta?M20%–32% and median progression?free survival of ~7 months, positioning it as a potentially company?building, first?in?class EpCAM ADC.
• Enrollment in dose?optimization is complete (40 patients at 8.6 mg/kg and 10 mg/kg; 113 total in the Phase I), and management is targeting a registrational late?line CRC study in the first half of 2027 with a comprehensive Phase I update planned in H2 2026 to inform dose selection.
• Updated adverse?event management (prophylactic loperamide and budesonide, adjusted ideal body weight dosing) appears to lower high?grade diarrhea (initially ~10% in early optimization patients), but longer follow?up and broader data are needed to confirm tolerability and impact on overall survival.
• CytomX is advancing Varseta?M into combination studies—bevacizumab combo data expected by H1 2027 and a chemo (bevacizumab + 5?FU/leucovorin) Phase I/II starting in H2 2026—and plans Phase I expansions in other EpCAM?expressing tumors to pursue pan?tumor potential.
• Following a March financing, CytomX ended Q1 with $346.7M in cash and expects runway into at least H2 2028, which management says is sufficient to advance Varseta?M into a registrational study and support planned clinical milestones.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX traded down $0.02 during trading on Friday, hitting $3.98. 5,054,790 shares of the stock were exchanged, compared to its average volume of 3,705,994. CytomX Therapeutics has a 1-year low of $0.91 and a 1-year high of $8.21. The company has a market capitalization of $677.36 million, a price-to-earnings ratio of -9.71 and a beta of 2.18. The company’s fifty day simple moving average is $4.66 and its 200-day simple moving average is $4.53.

Insider Transactions at CytomX Therapeutics

In other news, CEO Sean A. Mccarthy sold 118,969 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total transaction of $763,780.98. Following the sale, the chief executive officer owned 1,078,922 shares of the company’s stock, valued at approximately $6,926,679.24. This trade represents a 9.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Marcia Belvin sold 31,492 shares of CytomX Therapeutics stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the sale, the senior vice president directly owned 300,760 shares in the company, valued at $1,930,879.20. The trade was a 9.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 191,063 shares of company stock worth $1,226,624 over the last quarter. 6.60% of the stock is owned by company insiders.

Institutional Trading of CytomX Therapeutics

Several institutional investors have recently modified their holdings of the company. Hsbc Holdings PLC acquired a new stake in shares of CytomX Therapeutics during the 4th quarter worth approximately $52,000. Empowered Funds LLC acquired a new stake in shares of CytomX Therapeutics during the 4th quarter worth approximately $133,000. XTX Topco Ltd grew its holdings in shares of CytomX Therapeutics by 63.9% during the 4th quarter. XTX Topco Ltd now owns 47,991 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 18,705 shares in the last quarter. Virtus Investment Advisers LLC bought a new position in shares of CytomX Therapeutics during the 4th quarter worth approximately $270,000. Finally, Twinbeech Capital LP bought a new position in shares of CytomX Therapeutics during the 4th quarter worth approximately $75,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on CTMX shares. Barclays upped their price target on CytomX Therapeutics from $10.00 to $16.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. HC Wainwright upped their price target on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 16th. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $7.00 to $12.00 in a report on Monday, March 16th. Oppenheimer reiterated an “outperform” rating and set a $12.00 price target on shares of CytomX Therapeutics in a report on Monday, March 16th. Finally, Wall Street Zen upgraded CytomX Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.44.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.